Beyond T-Cells: Functional Characterization of CTLA-4 Expression in Immune and Non-Immune Cell Types

Damilola Oyewole-Said 1, Vanaja Konduri 1, Jonathan Vazquez-Perez 1, Scott A. Weldon 2, Jonathan M. Levitt 1,3,4 and William K. Decker 1,3,5*

1 Department of Pathology & Immunology, Baylor College of Medicine, Houston, TX, United States, 2 Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX, United States, 3 Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX, United States, 4 Scott Department of Urology, Baylor College of Medicine, Houston, TX, United States, 5 Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, United States

The immune response consists of a finely-tuned program, the activation of which must be coupled with inhibitory mechanisms whenever initiated. This ensures tight control of beneficial anti-pathogen and anti-tumor responses while preserving tissue integrity, promoting tissue repair, and safeguarding against autoimmunity. A cogent example of this binary response is in the mobilization of co-stimulatory and co-inhibitory signaling in regulating the strength and type of a T-cell response. Of particular importance is the costimulatory molecule CD28 which is countered by CTLA-4. While the role of CD28 in the immune response has been thoroughly elucidated, many aspects of CTLA-4 biology remain controversial. The expression of CD28 is largely constrained to constitutive expression in T-cells and as such, teasing out its function has been somewhat simplified by a limited and specific expression profile. The expression of CTLA-4, on the other hand, while reported predominantly in T-cells, has also been described on a diverse repertoire of cells within both lymphoid and myeloid lineages as well as on the surface of tumors. Nonetheless, the function of CTLA-4 has been mostly described within the context of T-cell biology. The focus on T-cell biology may be a direct result of the high degree of amino acid sequence homology and the co-expression pattern of CD28 and CTLA-4, which initially led to the discovery of CTLA-4 as a counter receptor to CD28 (for which a T-cell-activating role had already been described). Furthermore, observations of the outsized role of CTLA-4 in T_{reg} mediated immune suppression and the striking phenotype of T-cell hyperproliferation and resultant disease in CTLA-4−/− mice contribute to an appropriate T-cell-centric focus in the study of CTLA-4. Complete elucidation of CTLA-4 biology, however, may require a more nuanced understanding of its role in a context other than that of T-cells. This makes particular sense in light of the remarkable, yet limited utility of anti-CTLA-4 antibodies in the treatment of cancers and of CTLA-4-Ig in autoimmune disorders like rheumatoid arthritis. By fully deducing the biology...
of CTLA-4-regulated immune homeostasis, bottlenecks that hinder the widespread applicability of CTLA-4-based immunotherapies can be resolved.

**Keywords: CTLA-4, peripheral tolerance, immune regulation, tumor immunity, CD28**

**INTRODUCTION**

CD28 and CTLA-4 are homologous glycoproteins of the immunoglobulin superfamily (1). Despite their shared ability to bind CD80/B7.1 and CD86/B7.2 (B7 proteins) (2, 3), these molecules mediate opposing effects on T-cell function. While CD28 promotes T-cell activation and proliferation (4, 5), CTLA-4 is reported to dampen T-cell responses through a variety of mechanisms (6–12). Prior to activation, conventional T-cells (Tconv) express low levels of CTLA-4, predominantly in intracellular compartments. Upon activation, CTLA-4 expression is upregulated and becomes increasingly detectable on the cell surface, peaking around 36 h post-activation (13–15). In Tregs on the other hand, transmembrane CTLA-4 is constitutively expressed and plays an integral role in Treg homeostasis and function (16–18). In general, T-cell CTLA-4 is largely constrained to intracellular expression although some surface expression may be detectable owing to the rapid, continuous shuffling of CTLA-4 between intracellular compartments and the plasma membrane (10, 19–22).

Intracellular trafficking of CTLA-4 requires the recruitment of a specific repertoire of proteins by vesicle-bound-intracellular CTLA-4 and by CTLA-4 at the plasma membrane (9, 23). These protein–protein interactions are largely mediated by the recruitment of the clathrin adaptor complexes AP-1 (at the trans-golgi) and AP-2 (at the plasma membrane) by the intracellular YVKM motif of CTLA-4 (10, 19, 20, 24, 25). Tight control of turnover is another important regulator of CTLA-4 expression and function. Specifically, lipopolysaccharide-responsive and beige-like anchor protein (LRBA) protects CTLA-4 from lysosomal degradation thus promoting its accumulation in the cytoplasm and subsequent surface expression (26). Although LRBA deficiency presents with a variable phenotype (26, 27), autoimmunity and hypogammaglobulinemia characterized by decreased Treg, total B-cell, class-switched B-cell and plasmablast frequency along with an increased proportion of circulating Tfh are prevalent (27–30). In these patients, CTLA-4-mediated functions can be substantially impaired (26–31).

The most widely reported mechanism of CTLA-4-mediated inhibition is its competitive binding of B7 proteins to which it has a 10–100-fold greater affinity than CD28 (32, 33). As a result, T-cells are deprived of CD28-mediated activating signals. Subsequent to binding B7 proteins, CTLA-4 has also been described to further deprive T-cells of stimulatory signaling via transendocytosis of B7 molecules from the surface of APCs (11, 22), inhibition of proximal T-cell receptor (TCR) signaling (6), and disruption of the c-SMAC (central supramolecular cluster) within the immunological synapse (34). The disruption of CD28 signaling is generally accepted as the major pathway through which CTLA-4 functions as evidenced by observations that fatal lymphoproliferation observed in CTLA-4−/− mice is rescued by the genetic deletion of CD28 (35).

Aside from these cell-extrinsic mechanisms, CTLA-4 has also been shown to function through cell-intrinsic mechanisms. Upon binding of B7 molecules, CTLA-4 has been reported to signal through PI3K and PKCθ in activated conventional T-cells (23, 36, 37). In these cells, CTLA-4 signaling reinforces its previously described inhibitory role by recruiting the phosphatases SHP-2 and PP2A to the immunological synapse, thereby reversing the phosphorylation of secondary messengers by TCR co-receptors and co-stimulatory molecules (38–41). This cell-intrinsic program also serves to limit the contact-dependent suppressive capacity of Tregs through PKCθ signaling (7) and prevent activation-induced cell death, particularly in T1f2 cells, by promoting Bcl2 expression while downregulating Fasl (42). In addition, CTLA-4 ligation enforces a reversal of the TCR stop signal which may decrease the contact time between T-cells and APCs and could also explain the apparent ability of CTLA-4 to drive T1f1 cell migration to secondary lymphoid organs (37, 43).

**B-CELLS**

While the T-cell phenotype in CTLA-4−/− mice is striking and largely accounts for the observed tissue destruction, B-cells in these mice also displayed a hyperactivated phenotype. This distinctive B-cell signature includes hypergammaglobulinemia as well as upregulated expression of CD86, FAS and CD5 on B-cells (44). Accordingly, CTLA-4 expression in B-cells was subsequently demonstrated (31, 45–48). Coupled with reports of auto-antibody production and deficiencies in antigen-specific antibody generation in LRBA-deficient patients (29), these observations provided the rationale for studying CTLA-4 in the context of B-cell activation. Initial reports indicated that the role of CTLA-4 in limiting B-cell responses was mediated via Tfh, Tfreg, and Treg expression of CTLA-4 (49). The authors reported that CTLA-4-mediated control of B-cell activation could occur within or outside of the germinal center and could occur independently of CD80 and CD86. The experiments outlined in this report demonstrated, for the first time, that CTLA-4 could extrinsically subvert B-cell activation. The observations, however, did not preclude cell-intrinsic mechanisms of CTLA-4-mediated constraint of B-cell responses.

Aside from the expression of CTLA-4 on human B-cell chronic lymphocytic leukemia (discussed in ‘Tumors’ section), the expression of CTLA-4 on B1 and B2 B-cells has been sparsely studied but well-validated in mice and humans. The stimuli which drive B2 B-cell expression of CTLA-4 remain controversial, however. Some reports assert that B2 B-cell CTLA-4 expression may be driven by PMA, LPS + IL-4, or CD40 + IL-4 stimulation.
transfer of CTLA-4 from T-cells to co-cultured B2 B-cells was disappearing by 96 h after stimulation (48). Importantly, the activated T-cells and was transient, peaking within 48 h and other hand, are commonly taken to be the conventional B-cell are the brokers of innate humoral responses. B2 B-cells, on the other hand, are commonly taken to be the conventional B-cell subset. They participate in the adaptive immune response, generating highly specific antibodies in a T-cell-dependent or independent manner during the later phase of an immune response. In contrast to B1 B-cells, these cells are generally located in the bone marrow and secondary lymphoid organs. Additionally, B2 B-cells may be recruited to peripheral organs during an immune response. In B2 B-cells, surface CTLA-4 expression was reported to be fivefold lower than observed in activated T-cells and was transient, peaking within 48 h and disappearing by 96 h after stimulation (48). Importantly, the transfer of CTLA-4 from T-cells to co-cultured B2 B-cells was ruled out by virtue of the observation that CTLA-4+/− B2-cells remain negative upon co-culture with CTLA-4-sufficient T-cells. Although B2 B-cell CTLA-4 was not required for B-cell differentiation or homeostasis in mice (48), it was reported to restrain isotype switching. Particularly, CTLA-4 ligation limited the production of antigen-specific and total IgM, IgG and IgE (46, 48) but not of natural antibodies (48). CTLA-4 ligation by human B2 B-cells led to the downregulation of surface and secreted IgG as well as IL-8, TNFα and IL-10 (45). In contrast, the role of CTLA-4 in B1 B-cell development and function remains undefined, although its expression has been reported (51). Given the reported lack of alterations to natural antibody production in CTLA-4+/− mice, it is possible that B1 CTLA-4 exerts a cell-extrinsic inhibitory function on the immune response.

Whether B-cell CTLA-4, in fact, possesses cell-extrinsic functions remains to be determined. As previously stated, LRBA-deficient patients and mice (with limited surface CTLA-4 expression) present with diminished total B-cell, IgG class-switched B-cell and plasmablast numbers, accompanied by increased frequency of circulating Tfh and the generation of autoantibodies, despite reported hypogammaglobulinemia (26, 27, 29, 52). While the administration of CTLA-4-Ig alleviates the overall clinical phenotype and reduces Tfh dependence. Specifically, the B-cell:T-cell interactions and resultant signaling cascades that drive CTLA-4 expression in B-cells are unknown. Furthermore, the mechanisms through which B-cell CTLA-4 restrains antigen-specific IgM and IgE production have not been determined, although STAT6 and NFKB activation were shown to be suppressed upon B-cell CTLA-4 ligation. Furthermore, the expression and function of CTLA-4 on non-malignant human B-cells has not been investigated. These mechanisms could prove important for elucidating pathways involved in the generation of allergic and autoinflammatory diseases, particularly those with confirmed B-cell involvement.

**NK CELLS**

Accounts of CTLA-4 expression in NK cells are even more scarce than those in B-cells. Presently, our knowledge is based primarily on one mouse and one human study. Interestingly, although both studies are in agreement regarding the conditions which drive the expression of CTLA-4 in their respective model systems, they come to disparate conclusions regarding its function in NK cells. In mouse studies conducted by the Cerwenka group (53), only IL-2-primed NK cells and tumor-infiltrating NK cells were observed to express CTLA-4. Similar to T-cells, CTLA-4 expression in NK cells was largely constrained to intracellular compartments. Moreover, CTLA-4 levels in IL-2-primed mouse NK cells could be modulated by cytokine treatment in their in vitro culture system. In particular, the combination of IL-12 and IL-18 but not IL-15 synergized with IL-2 to further enhance CTLA-4 expression while TGF-β served to counteract CTLA-4 expression. These observations were recapitulated in human studies carried out by Lougaris et al (54). Similarly, IL-2-primed human NK cells expressed intracellular CTLA-4, which could be further increased by IL-12 + IL-18 treatment. Presumably, the impact of IL-12 and IL-18 on the expression of NK CTLA-4 is of physiological relevance, since these cytokines have already been described as important modulators of NK cell phenotype, especially in the context of NK-DC crosstalk. Specifically, DCs (and macrophages) secrete IL-12 and IL-18 which synergize to boost NK cell-mediated cytotoxicity, IFN-γ production, and IL2Rα expression (55, 56).

Regarding the function of NK CTLA-4, there is a disagreement between the mouse and human data. CTLA-4 ligation was shown
to be inhibitory to mouse NK cell function (53) while, conversely, the absence of such ligation in human NK cells resulted in limited function (54). Specifically, in mouse NK cells, CTLA-4 was shown to limit the expression of IFN-γ upon B7 ligation or co-culture with mature dendritic cells.

When mature DCs were pre-treated with CTLA-4-Ig before co-culture with NK cells, IFN-γ expression by NK cells was partially inhibited. This experiment indicated that CTLA-4 may mediate its inhibitory role partly through B7 blockade in mice (53). However, the role of CTLA-4 in NK cell cytotoxicity was not examined in this study. Although CTLA-4-regulated IFN-γ likely plays a salient role in NK-mediated immunity, understanding the role of CTLA-4 in NK-mediated cytotoxicity could be an equally important phenomenon that remains unexamined.

In human NK cells, CTLA-4 function was examined in the contexts of NK cell development, IFN-γ production, and cytotoxicity (54). Here, CTLA-4 haploinsufficiency was not observed to affect NK cell development; rather, it was shown to limit IFN-γ expression in response to cytokine stimulation as well as degranulation in response to target K562 cells. This was surprising given the inhibitory role already described for mouse NK CTLA-4 and both mouse and human T-cell CTLA-4. In light of the disagreement between human and mouse NK cell studies as well as the variable expression of CD28 (57, 58) on human NK cells [unlike mouse NK cells (53)], the role of NK cell CTLA-4 in the immune response of each organism must be thoroughly validated. It will be important to determine the function of NK CTLA-4 particularly at the early phase of an immune response, the time at which NK cells are most often activated.

## MONOCYTES AND DENDRITIC CELLS

The interaction between dendritic cells (DCs) and T-cells is critical to determining the type, strength, and likely the duration of T-cell-dependent immune responses. Not only do dendritic cells prime de novo T-cell activation, they also contribute to the dampening of T-cell responses through negative selection in the thymus and can induce tolerance or anergy in the periphery (59–61). While the expression of CTLA-4 has been reported for T-cells and DCs, investigations into the origins and function of T-cell CTLA-4 are far more numerous than similar explorations of DC CTLA-4. In addition to the regulation of T-cell responses, the interaction between DCs and NK cells as well as non-immune cells is important to regulating the overall immune response. While it has been demonstrated that ligation of CTLA-4 molecules on the surface of DCs can engender a tolerogenic DC phenotype involving IL-10 and IDO expression (62, 63), the direct impact of DC CTLA-4 on immune cell phenotype is unknown. Initial DC reports demonstrated that freshly isolated CD14+ human monocytes could express CTLA-4 (64). Like T-cell CTLA-4, this was largely restricted to intracellular compartments and could be upregulated by activation of Protein Kinase C (PKC) via treatment of monocytes with PMA and IFN-γ (64). These early observations made no conclusions as to whether these activated monocytes were differentiated into dendritic cells or macrophages, both of which could be derived from cultured monocytes. More recent investigations, however, determined that bone marrow monocyte-derived dendritic cells were capable of upregulating soluble and transmembrane isoforms of CTLA-4 upon maturation with LPS, Poly I:C or a cocktail of inflammatory cytokines (63, 65). Notably, immature DCs expressed little to no intracellular or surface CTLA-4. The expression of CTLA-4 in DCs was also determined to delineate a novel subset of regulatory DCs present in hepatocellular carcinoma patients. In these patients, CD14+ CTLA-4+ DCs also expressed the inhibitory molecules PD-1, IDO and IL-10 (62). Cross-linking of CTLA-4 in these DCs further enhanced the expression of IDO and IL-10, which presumably contributed to immunosuppression and subsequent tumor escape.

Due to the lack of homogeneity within the DC compartment, it became necessary to define which DC subsets expressed CTLA-4. It was determined that while both CD1a+ and CD1a− dendritic cells expressed intracellular CTLA-4 upon maturation, only CD1a+ DCs expressed measurable levels of surface CTLA-4 (66). Further functional characterization of DC CTLA-4 followed, leading to the determination that ligation of the molecule inhibited AP-1 and NFκB activity and suppressed DC maturation and proliferation (64). Such ligation also promoted the expression of IL-10 and suppressed IL-8 release and T-cell responses in vitro. Accordingly, CTLA-4 ligation did not significantly impact antigen presentation, since the molecule was minimally expressed on immature dendritic cells (64). Further studies by Halpert et al. demonstrated for the first time that CTLA-4 expressed by both human and mouse bone marrow or monocyte-derived DC was capable of exerting cell-extrinsic effects on neighboring dendritic cells. This work determined that CTLA-4 was packaged into extracellular vesicles (EVs) which could be taken up by neighboring dendritic cells. Upon uptake of these CTLA-4+ EVs, B7 expression on the surface of recipient dendritic cells was significantly downregulated (Figure 1). Furthermore, the expression of CTLA-4 by a dendritic cell vaccine was found to impact antitumor efficacy (65). siRNA-mediated knockdown of CTLA-4 in a DC vaccine significantly improved tumor control and survival, correlating with vastly increased frequency of activated CD8+ T-cells. This result was verified in human monocyte-derived DC which, following treatment with CTLA-4 siRNA, stimulated the proliferation of far greater numbers of IFN-γ+ CD8+ T-cells and far fewer CD4+ CD25+ Foxp3+ phenotypic Treg. Accordingly, the same authors subsequently demonstrated that secretion of microvesicular CTLA-4 by dendritic cells plays a critical role in the regulation of T<sub>H</sub> polarization and promulgation of T<sub>H</sub>1 immunity (67). Although some features of DC CTLA-4 physiology have been determined, several important aspects are yet to be resolved. For instance, the role of CTLA-4 on the development of DCs and on DC-mediated negative selection of T-cells is unknown. Likewise, the underlying mechanisms which drive the effects of DC CTLA-4 and CTLA-4+ EVs on other dendritic cells, T-cells and antitumor immunity are unknown. While the expression of DC
CTLA-4 in bone marrow-derived DCs has been thoroughly validated, it is unclear which in vivo DC subsets express CTLA-4 in a similar fashion. Our unpublished observations from mouse splenic DCs have revealed that the expression of CTLA-4 by DC subsets is indeed differential. We observed that cDC1 cells (conventional DC type 1) expressed significantly greater intracellular CTLA-4 levels than cDC2 cells, monocytes, monocyte-derived DCs and plasmacytoid DCs (pDCs). While monocytes expressed undetectable levels of intracellular CTLA-4, the remaining subsets expressed comparable levels of CTLA-4. This would mark the first report of CTLA-4 expression in cDC1, cDC2 and pDC subsets. Our report, in contrast to others (62–66), differs with regard to the distinct absence of CTLA-4 expression in monocytes. This disparity likely stems from our stringent gating of mouse DC subsets [as previously described (68)], which differs from the CD14-predicated gating of monocytes in previous reports. These observations, coupled with reports of CTLA-4 expression in MDSCs and M2 macrophages in HNSCC tumors (69), underscore the importance of investigating the physiology of CTLA-4 within the monocyte lineage, particularly its utility in type I and type II T-cell responses as well as in T-cell-independent responses.

TUMORS

The earliest report of CTLA-4 expression in tumors came from observations made in leukemias as well as Hodgkin’s and non-Hodgkin’s lymphomas (NHL) (70). CTLA-4 was detected on acute and chronic myeloid leukemias, large granular lymphocytic leukemia and malignant follicular B-cells of patients with low-grade B-cell lymphoma as well as non-malignant reactive B-cells in NHL patients. While CTLA-4 was detected in both B-cell chronic and acute lymphocytic leukemia, it was reported only in T-cell acute and not chronic lymphocytic leukemia (47, 70). CTLA-4 expression has also been reported in the lymphoblastic Raji and Daudi cell lines (71).

In patients with Hodgkin’s disease, CTLA-4 was not detected on any neoplastic lymphocytes and was notably absent in Reed-Sternberg cells (70). Although CTLA-4 is known as a negative regulator of T-cell proliferation, CTLA-4 expression was paradoxically detected on the malignant T-cells of patients with peripheral but not lymphoblastic or anaplastic Non-Hodgkin lymphomas (NHL) (70). While this expression of CTLA-4 on neoplastic peripheral T-cells would be in keeping with the inducible expression of CTLA-4 on activated T-cells, it calls into question the mechanisms that underlie the seeming loss of CTLA-4 expression on neoplastic T-cells.
of intrinsic CTLA-4-mediated control of T-cell proliferation (72, 73) as well as the activating signals which drive CTLA-4 expression in neoplasms. Perhaps CTLA-4 expression promotes tumor escape in the periphery (by inhibiting anti-tumor responses) but is incapable of inhibiting malignant lymphocyte proliferation through well-documented cell-intrinsic modes of immune suppression. Although these questions are yet to be resolved, observations derived from studies of B-cell CTLA-4 in CLL have revealed important clues that could mirror the physiology of CTLA-4 in T-cell malignancies (74, 75). It was observed that B-cell CTLA-4 was most highly expressed in the bone marrow and peripheral blood in comparison to lymph node B-cells where expression was significantly lower (76). In these malignant B-cells, CTLA-4 expression was constitutive and intracellular but could be driven to the surface via co-culture with activated T-cells. Here, neoplastic B-cell CTLA-4 successfully mediated transendocytosis of surface CD80 (from CD80-GFP+ cells) and downregulated IL-2 production by co-cultured T-cells (75). Functional characterization of tumor CTLA-4 function proceeded with the study of cell-intrinsic effects of CTLA-4 on B-cells in CLL. Here, decreased expression of CTLA-4 correlated with increased expression of c-Myc, phospho-STAT1, NFATc2, phospho-c-Fos, and Bcl2, molecules which presumably are downstream of B-cell Receptor (BCR) activation (76). Accordingly, CTLA-4 downregulation also correlated with decreased apoptosis in CLL B-cells. These lines of evidence suggest that neoplastic B-cell CTLA-4 is functionally suppressive through both cell-intrinsic and cell-extrinsic pathways. It would seem that malignant B-cell CTLA-4, at least, is capable of dampening T-cell-mediated anti-tumor immune responses while paradoxically limiting B-cell proliferation and survival. Perhaps there remains sufficient heterogeneity, with regard to CTLA-4 expression, such that lymphoproliferation can occur with CTLA4− malignant B-cells in the lymph node with concurrent inhibition of anti-tumor responses by CTLA-4+ malignant B-cells in peripheral blood or bone marrow, thus favoring overall tumor progression.

The prognostic value of B-cell CTLA-4 in CLL is not yet clear-cut. Some reports suggest that CTLA-4 expression promotes the survival of leukemic B-cells and correlates with disease progression (74, 76), while others assert that CTLA-4 expression may be a marker of improved outcomes (77). This prognostic mirrors the disparate conclusions that have been drawn regarding the expression of CTLA-4 in non-immune cell malignancies. In some breast cancers (78, 79), thymomas (80), esophageal carcinomas (81) and nasopharyngeal carcinomas (82), tumor expression of CTLA-4 correlated with poor prognosis while no relationship to survival was observed with testicular germ cell tumors (83). Although the basis for the negative correlation of CTLA-4 expression to prognosis was not determined in the relevant studies, it is possible (perhaps even probable) that such poor prognoses were mediated by the direct suppression of immune effector cell function by CTLA4+ tumor tissue. A cogent demonstration of this immune suppression was demonstrated in breast cancer cells, which have been shown to express CTLA-4. In this study, CTLA-4+ breast cancer cells suppressed dendritic cell maturation, antigen presentation, and inflammatory cytokine expression, ultimately dampening T\textsubscript{H}1 and CTL responses (79). Yet, in non-small cell lung cancer (NSCLC) (84) and when expressed in the hepatic hilar region of extrahepatic bile duct cancer patients (85), studies determined that CTLA-4 correlated with improved survival. However, later studies showed that disease-specific survival did not correlate with primary tumor CTLA-4 expression (86). Rather, the prognostic value of CTLA-4 in NSCLC could only be revealed when patients were stratified by disease subtype. Here, metastatic lymph node expression of CTLA-4 correlated with poor prognosis while soluble CTLA-4 expression predicted improved prognosis in squamous cell carcinoma. CTLA-4 is reported to be highly expressed in most human and mouse melanoma cell lines as well as normal melanocytes, many primary melanomas, and melanoma stem cells with conflicting data suggesting both immune and non-immune-related roles in tumorigenesis (87–89). Altogether, the disparate effects of tumor CTLA-4 expression make a strong case for studying the effects of CTLA-4 expression within each separate microenvironment in each cancer type and at different stages of cancer progression, rather than extrapolating results from one cancer type.

**NON-HEMATOPOIETIC/NON-CANCER**

The study of CTLA-4 expression and function has so far been centered on hematopoietic lineages and anti-tumor responses. While the immunological role of CTLA-4 is indisputable, it is clear that the function of CTLA-4, particularly in the maintenance of tissue homeostasis and tolerization at immune-privileged sites, may be more nuanced than has been described. Moreover, immunological roles such as the ability to secrete cytokines and antimicrobial peptides in response to immune stimuli have been observed in non-hematopoietic cells (90–94). Non-hematopoietic cells have also been reported to engage hematopoietic cells, direct their differentiation, and drive autoimmune disease development (91, 93–95). Importantly, CTLA-4 polymorphisms have been linked to autoimmune conditions including type 1 diabetes (96, 97), Hashimoto’s thyroiditis (97, 98), systemic lupus erythematos (99, 100) and celiac disease (101), indicating possible roles for non-hematopoietic tissue CTLA-4 in the ontogeny and progression of autoimmune disease. As such, investigations into the expression pattern and function of CTLA-4 in non-tumor and non-hematopoietic tissue is warranted. In this regard, CTLA-4 expression has been reported in mesenchymal stem cells and placental fibroblasts (102, 103) as well as the aforementioned normal melanocytes. Additionally, stimulation of cultured muscle cells with IL-1α IFN-γ or IL-2 + anti-CD28 promoted CTLA-4 expression (104).

In general, human mesenchymal stem cells (MSCs) are highly immunosuppressive and have been theorized to exert their effects through a variety of mechanisms (reviewed elsewhere) (105). While the release of HLA-G and factors such as nitric oxide and PGE\textsubscript{2} have been identified as mechanisms of MSC-induced
| Cell type | Experimental Evidence | Controls | Anti-CTLA-4 clone | Reference |
|-----------|------------------------|----------|-------------------|-----------|
| B-cells   | A. Flow cytometry (45–48, 50) | CTLA-4-tg-transfected J558L murine myeloma (47), T-cells and isotype controls (45–48, 50). | BNI3 (47) | (45–48, 50) |
|           | B. Immunoprecipitation + western blot (50) | | | |
|           | C. RT-PCR (48) | | | |
|           | D. Analysis of bone marrow- chimeric mice (48) | | | |
|           | E. Functional analysis of anti-CTLA-4-mediated cross-linking (46) | | | |

| B1 B-cells (mouse) | Post-hoc analysis of publicly-available B-cell microarray datasets | Not provided | Not provided | (51) |

| NK Cells | IL-2-primed mouse NK cells | A. Flow cytometry | Isotype control for functional analyses, isotype controls for flow cytometry. | UC10-4F10-11 and UC10-4B9 | (53) |
|          |                          | B. qRT-PCR | | |
|          |                          | C. Functional analyses using CTLA-4-Fc and NK cells from CTLA-4 KO mice | | |

| IL-2-primed human NK cells | Flow cytometry | CTLA-4 haploinsufficient patient samples, isotype control. | Not provided | (54) |

| Monocytes and DCs | CD14+ Human monocytes | A. Flow Cytometry (63, 64) | CTLA-4-tg-transfected J558L murine myeloma (63), T-cells (64), isotype control (47, 63, 64), C33a cervical cancer cell line and surface staining of resting T-cells (64). | BNI3 (63); N-19 and AF-386-PB (64) | (47, 63, 64) |
|                  |                          | B. Fluorescence microscopy (64) | | |
|                  |                          | C. Western blot (64) | | |
|                  |                          | D. RT-PCR (64) | | |

| Human monocyte-derived dendritic cells | A. Flow Cytometry (63, 65, 66) | PBMC (63, 65, 66), T-cells (65), isotype control (63, 65, 66), competitive antibody binding, non-targeting siRNA (65). | BNI3 and A3.6B10.G1 (63); 48815, 14D3 and agonist 3D5 (63) | (63, 65, 66) |
|                                       | B. Western blot (65, 66) | | | |
|                                       | C. Confocal microscopy (65) | | | |
|                                       | D. siRNA knockdown (65) | | | |
|                                       | E. Immunoprecipitation (65) | | | |
|                                       | F. RT-PCR and PCR product sequencing (65, 66) | | | |

| Mouse bone marrow-derived dendritic cells | A. siRNA knockdown and western blot | Non-targeting siRNA | Not provided | (63, 65, 66) |
|                                          | B. siRNA knockdown with functional analysis | | | |

| MDSCs and Macrophages | Mouse MDSCs (CD11b+Gr-1+) and M2 macrophages (CD11b+F4/80+) | A. Flow cytometry | Isotype control | Not provided | (69) |
|                       |                          | B. Fluorescence microscopy | | |

| Granulocytes | G-CSF-treated human granulocytes | Flow cytometry | CTLA-4-tg-transfected J558L murine myeloma, T-cells, isotype controls. | BNI3 | (47) |

| CD34+ hematopoietic stem cells | A. Flow cytometry | CTLA-4-tg-transfected J558L murine myeloma, T-cells, isotype controls. | BNI3 | (47) |
|                                | B. Immunohistochemistry | | |

| Immune cell malignancies | Non-Hodgkin’s B-cell lymphoma (follicular) | Immunohistochemistry | CTLA-4-transfected cells and reactive lymph node samples, Jurkat cells | BNI3 | (70) |
|                          | T-cell lymphoma (peripheral), T-CLL | Immunohistochemistry | CTLA-4-transfected cells and reactive lymph node samples, Jurkat cells | BNI3 | (70) |

(Continued)
### TABLE 1 | Continued

| Cell type                                      | Experimental Evidence                                                                 | Controls                                                                 | Anti-CTLA-4 clone          | Reference       |
|------------------------------------------------|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------|----------------------------|-----------------|
| B-Chronic lymphocytic leukemia (human and TCL1 transgenic mice) | A. Microarray ([75–77](#))  
B. Flow Cytometry ([47, 75–77](#))  
C. RT-PCR ([75, 76](#))  
D. siRNA knockdown ([76](#))  
E. Western blot ([76](#)) | Isotype control ([75, 76](#)), CTLA-4-Ig-transfected J558L murine myeloma ([47](#)), T-cells ([47](#)), Jurkat cells ([75](#)), scrambled siRNA ([76](#)) | BNI3 ([47, 79](#)), UC10-4F10-11 ([75](#)), 9d9 ([75](#)), ([47, 75–77](#)) | ([47, 75–77](#)) |
| AML, CML, B-ALL, T-CLL, LGL                      | A. Flow cytometry                                                                      | CTLA-4-Ig-transfected J558L murine myeloma, T-cells, isotype controls,  | BNI3 ([47](#))             | ([47](#))       |
| Raji and Daudi B-lymphoblastoid cell lines       | A. Flow Cytometry ([47, 71](#))  
B. RT-PCR + nested PCR ([47](#)) | T-cells ([47, 71](#)), CTLA-4-Ig-transfected J558L murine myeloma ([47](#)), and isotype controls ([47, 71](#)) | BNI3 ([47](#))             | ([47, 71](#))   |
| Human breast cancer cells and cell lines (MDA-MB-231, MCF-7, SKBR3 and T47D) | A. Flow cytometry ([79](#))  
B. Functional analyses with antibody blockade ([79](#))  
C. Immunohistochemistry ([78, 112](#)) | Isotype control ([79](#)), human tonsil section ([78, 79, 112](#)), non-neoplastic breast epithelial tissue ([78](#)), primary antibody solution pre-cleared with CTLA-4 peptide ([78](#)) and sections stained with primary antibody-free diluent ([78](#)) | 14D3 ([79](#)), bs-1179R ([78, 79](#)), F8 ([78, 79, 112](#)) | ([78, 79, 112](#)) |
| Melanoma                                        | A. Flow cytometry  
B. Immunohistochemistry  
C. qRT-PCR  
D. ELISA (soluble CTLA-4) | Isotype control 14D3, Ipilimumab                                         | ([113](#))                 | ([113](#))     |
| Esophageal carcinoma                            | Immunohistochemistry                                                                   | Not provided                                                            | EPR1476 ([81](#))          | ([81](#))       |
| Nasopharyngeal carcinoma                        | Immunohistochemistry                                                                   | Not provided                                                            | Polyclonal antibody ([251548 Abbiotec](#)) | ([82](#))       |
| Non-small cell lung cancer (NSCLC)               | Immunohistochemistry                                                                   | Not provided                                                            | 14D3 ([84](#)), ([86](#)) | ([84, 86](#))   |
| Cholangiocarcinoma (extrahepatic bile duct cancer) | Immunohistochemistry                                                                   | Not provided                                                            | Polyclonal (Abcam ab151773) ([85](#)) | ([85](#))       |
| Testicular germ cell cancer                      | A. Immunohistochemistry  
B. Analysis of TCGA datasets (mRNA) | Normal human placenta and tonsil tissue                                  | Polyclonal (Thermofisher) ([83](#)) | ([83](#))       |
| Non tumor/non-hematopoietic Mesenchymal stem cells | A. RT-PCR  
B. Western blot  
C. Flow cytometry  
D. Soluble CTLA-4 ELISA  
E. Functional studies with CTLA-4 Ig blockade | Isotype control  | BNI3 ([103](#)) | ([103](#))   |
| Placental fibroblast                             | A. RT-PCR  
B. Immunohistochemistry                                                                 | Isotype control and activated T-cells                                    | Not provided               | ([102](#))     |
| Keratinocytes and cervical epithelium (HPVE7-induced) | A. Microarray  
B. RT-PCR  
C. Western blot  
D. Flow cytometry  
E. Immunohistochemistry                                                                 | Isotype control  | BNI3 ([108](#)) | ([108](#))   |
immunosuppression, no consensus has been reached regarding the dominant mode of immune inhibition. These cells predominantly expressed the full-length CTLA-4 (flCTLA-4) and secreted soluble CTLA-4 (sCTLA-4), although other isoforms were also detected. MSC CTLA-4 was determined to inhibit TNFα production by PHA-activated PBMCs, a phenomenon that was boosted by hypoxic conditions. Accordingly, hypoxic culture conditions significantly upregulated the expression of flCTLA-4 and sCTLA-4 in MSCs (103).

Efforts to define the immunosuppressive landscape of the maternal-fetal landscape during pregnancy led to the discovery that fetal cells expressed CTLA-4 during gestation. Notably, cultured human placental fibroblasts and mesenchyme as well as placentas from all gestational time points expressed CTLA-4 (102).

In the same vein, viral infections, such as with Human Papilloma Virus (HPV) have been demonstrated to imprint an immunosuppressive phenotype upon the host organism (106, 107). HPV, in particular, has been shown to impair host NK and T-cell antiviral responses through a variety of mechanisms including Treg recruitment, inhibition of DC maturation and suppression of NK cell cytotoxicity. In keeping with this theme, the HPV protein HPVE7, has been reported to induce CTLA-4 expression in human cervical epithelium and keratinocytes by promoting H3K36me2 at the CTLA-4 promoter (108). While no functional characterization of CTLA-4 in this context has been carried out, the authors hypothesize that it may contribute to the immunosuppressive phenotype and subsequent immune escape engendered by HPV.

CONCLUSIONS

The original characterizations of CTLA-4 function and biology were driven by the dramatic T-cell-intrinsic phenotype observed in global knockout mice, animals that were born normal but died in the early postnatal period of massive and uncontrolled lymphoproliferation (44, 109). When follow-up studies that included concomitant global deletion of CD28 (110) as well as re-expression of CTLA-4 in null mice from the T-cell-specific Lck promoter (111) both rescued this dramatic but early phenotype, there remained little impetus to look for additional mechanisms of action outside the T-cell compartment. In contrast to this early paradigm, studies over the last two decades have demonstrated both constitutive and inducible expression of CTLA-4 in a broad distribution of tissues and cell types (Table 1). This expansive pattern of expression and the circumstances under which induction may occur have necessitated a reevaluation of the role that CTLA-4 plays in global immune regulation. A variety of convincing studies (Table 1), particularly those in dendritic cells and tumors, now demonstrate that CTLA-4 plays nonredundant and critical roles in thymic development, T-cell priming, peripheral tolerance, and a variety of other critical immunoregulatory functions. Further, it appears likely that additional roles for this central and highly versatile molecule will be uncovered as additional studies progress.

AUTHOR CONTRIBUTIONS

DO-S, VK, JV-P, JL, and WD all collaborated in the writing and editing of this manuscript. SW provided the original artwork. All authors contributed to the article and approved the submitted version.

FUNDING

This work was funded in part by NIH R01 AI127387 to WD.

REFERENCES

1. Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, et al. A new member of the immunoglobulin superfamily―CTLA-4. Nature (1987) 328(6127):267–70. doi: 10.1038/328267a0
2. Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, et al. B7 antigen is a second ligand for CTLA-4 and CD28. Nature (1993) 366(6450):76–9. doi: 10.1038/366076a0
3. Linsley PS, Brady W, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med (1990) 174(3):561–9. doi: 10.1084/jem.174.3.561
4. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med (1991) 173(3):721–30. doi: 10.1084/jem.173.3.721
5. Turka LA, Ledbetter JA, Lee K, June CH, Thompson CB. CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD3+ mature thymocytes. J Immunol (1990) 144(5):1646–53.
6. Guntermann C, Alexander DR. CTLA-4 suppresses proximal TCR signaling in resting human CD4(+) T cells by inhibiting ZAP-70 Tyr(319) phosphorylation: a potential role for tyrosine phosphatases. J Immunol (2002) 168(9):4420–9. doi: 10.4049/jimmunol.168.9.4420
7. Kong KF, Fu G, Zhang Y, Yokosuka T, Casas J, Canonigo-Balancio AJ, et al. Protein kinase C-ε controls CTLA-4-mediated regulatory T cell function. Nat Immunol (2014) 15(5):665–72. doi: 10.1038/nature13666
8. Paterson AM, Lovitch SB, Sage PT, Junjea VR, Lee Y, Trombley JD, et al. Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity. J Exp Med (2015) 212(10):1603–21. doi: 10.1084/jem.20141030
9. Pentcheva-Hoang T, Egen JG, Wojnoonski K, Allison JP. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity (2004) 21(3):401–13. doi: 10.1016/j.immuni.2004.06.017
10. Qureshi OS, Kaur S, Hou TZ, Jeffery LE, Poulter NS, Briggs Z, et al. Constitutive clathrin-mediated endocytosis of CTLA-4 persists during T cell activation. J Biol Chem (2012) 287(12):9429–40. doi: 10.1074/jbc.M111.304329
11. Hou TZ, Qureshi OS, Wang CJ, Baker J, Young SP, Walker LS, et al. A transendocytosis model of CTLA-4 function predicts its suppressive behavior on regulatory T cells. J Immunol (2015) 194(5):2148–59. doi: 10.4049/jimmunol.1401876
12. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med (1995) 182(2):459–65. doi: 10.1084/jem.182.2.459
13. Perez-Garcia A, Osca G, Bosch-Vizcaya A, Kelleher N, Santos NY, Rodriguez R, et al. Kinetics of the CTLA-4 isoforms expression after...
T-lymphocyte activation and role of the promoter polymorphisms on CTLA-4 gene transcription. *Hum Immunol* (2013) 74(9):1219–24. doi: 10.1016/j.humimm.2013.05.012.

14. Perkins D, Wang Z, Donovan C, He H, Mark D, Guan G, et al. Regulation of CTLA-4 expression during T cell activation. *J Immunol* (1996) 156(11):4154–9.

15. Lindsten T, Lee KP, Harris ES, Petryniak B, Craighead N, Reynolds PJ, et al. Characterization of CTLA-4 structure and expression on human T cells. *J Immunol* (1993) 151(7):3489–99.

16. Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T, Miyara M, Fehervari Z, et al. Regulation of cistrome by CTLA-4. *Proc Natl Acad Sci U S A* (2000) 97(14):7503–8. doi: 10.1073/pnas.97.14.7503.

17. Shiratori T, Miyatake S, Ohno H, Nakaseko C, Isono K, Bonifacino JS, et al. Tyrosine phosphorylation controls internalization of CTLA-4 by regulating its interaction with clathrin-associated adaptor complex AP-2. *Immunity* (1997) 6(5):583–9. doi: 10.1016/S1074-7613(00)80346-5.

18. Read S, Greenwald R, Izdey A, Robinson N, Mandelbrot D, Francisco L, et al. Characterization of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. *J Immunol* (2006) 177(7):4376–83. doi: 10.4049/jimmunol.177.7.4376.

19. Chuang E, Alegre ML, Dukett CS, Noel PJ, Vander Heiden MG, Thompson science.1202947. doi: 10.1084/jem.185.3.393.

20. Shiratori T, Miyatake S, Ohno H, Nakaseko C, Isom K, Bonifacino JS, et al. Regulation of cistrome by CTLA-4. *Proc Natl Acad Sci U S A* (2000) 97(14):7503–8. doi: 10.1073/pnas.97.14.7503.

21. Banton MC, Inker KL, Valk E, Rudd CE, Schneider H. Rab8 binding to its interaction with clathrin-associated adaptor complex AP-2. *Immunity* (1997) 6(5):583–9. doi: 10.1016/S1074-7613(00)80346-5.

22. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-intrinsic function of CTLA-4. *J Immunol* (2006) 313(6):2026–32. doi: 10.4049/jimmunol.177.7.4376.

23. Schneider H, Prasad K, Shoelson SE, Rudd CE. CTLA-4 binding to the lipid kinase phosphatidylinositol 3-kinase in T cells. *J Exp Med* (1995) 181(1):351–5. doi: 10.1084/jem.181.1.351.

24. Nieves ES, Anishina A, van den Zeijl MA, van der Heijden MG, Thompson science.1202947. doi: 10.1084/jem.185.3.393.

25. Knieke K, Lingel H, Chamaon K, Brunner-Weinzierl MC. Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activation. *PloS One* (2012) 7(3):e31939. doi: 10.1371/journal.pone.0031939.

26. Marengere LE, Waterhouse P, Duncan GS, Mittrucker HW, Feng GS, Mak TW. Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. *Science* (1996) 272(5265):1170–3. doi: 10.1126/science.272.5265.1170.

27. Lee KM, Chuang E, Griffin M, Khattar R, Hong DK, Zhang W, et al. Molecular basis of T cell inactivation by CTLA-4. *Science* (1998) 282(5397):2263–6. doi: 10.1126/science.282.5397.2263.

28. Teft WA, Chau TA, Madrenas J. Structure-Function analysis of the CTLA-4 interaction with PP2A. *RMC. Immunol* (2009) 10:23. doi: 10.1186/1471-2172-10-23.

29. Baroja ML, Vijayakrishnan L, Betteili E, Darlington Pl, Chau Ta, Ling V, et al. Inhibition of CTLA-4 function by the regulatory subunit of serine/threonine phosphatase 2A. *J Immunol* (2002) 168(10):5070–8. doi: 10.4049/jimmunol.168.10.5070.

30. Pandiyan P, Gartner D, Soezeri O, Radbruch A, Schulze-Osthoff K, Brunner-Weinzierl MC. CD152 (CTLA-4) regulates gene expression in activated B cells. *J Exp Med* (2004) 199(6):831–42. doi: 10.1084/jem.20031058.

31. Schneider H, Downey J, Lingel H, Chamaon K, Brunner-Weinzierl MC. Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activation. *PloS One* (2012) 7(3):e31939. doi: 10.1371/journal.pone.0031939.

32. Schneider H, Downey J, Lingel H, Chamaon K, Brunner-Weinzierl MC. Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activation. *PloS One* (2012) 7(3):e31939. doi: 10.1371/journal.pone.0031939.

33. Schneider H, Downey J, Lingel H, Chamaon K, Brunner-Weinzierl MC. Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activation. *PloS One* (2012) 7(3):e31939. doi: 10.1371/journal.pone.0031939.

34. Schneider H, Downey J, Lingel H, Chamaon K, Brunner-Weinzierl MC. Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activation. *PloS One* (2012) 7(3):e31939. doi: 10.1371/journal.pone.0031939.

35. Schneider H, Downey J, Lingel H, Chamaon K, Brunner-Weinzierl MC. Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activation. *PloS One* (2012) 7(3):e31939. doi: 10.1371/journal.pone.0031939.

36. Schneider H, Downey J, Lingel H, Chamaon K, Brunner-Weinzierl MC. Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activation. *PloS One* (2012) 7(3):e31939. doi: 10.1371/journal.pone.0031939.

37. Schneider H, Downey J, Lingel H, Chamaon K, Brunner-Weinzierl MC. Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activation. *PloS One* (2012) 7(3):e31939. doi: 10.1371/journal.pone.0031939.

38. Schneider H, Downey J, Lingel H, Chamaon K, Brunner-Weinzierl MC. Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activation. *PloS One* (2012) 7(3):e31939. doi: 10.1371/journal.pone.0031939.

39. Schneider H, Downey J, Lingel H, Chamaon K, Brunner-Weinzierl MC. Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activation. *PloS One* (2012) 7(3):e31939. doi: 10.1371/journal.pone.0031939.

40. Schneider H, Downey J, Lingel H, Chamaon K, Brunner-Weinzierl MC. Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activation. *PloS One* (2012) 7(3):e31939. doi: 10.1371/journal.pone.0031939.

41. Schneider H, Downey J, Lingel H, Chamaon K, Brunner-Weinzierl MC. Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activation. *PloS One* (2012) 7(3):e31939. doi: 10.1371/journal.pone.0031939.

42. Schneider H, Downey J, Lingel H, Chamaon K, Brunner-Weinzierl MC. Migration of Th1 lymphocytes is regulated by CD152 (CTLA-4)-mediated signaling via PI3 kinase-dependent Akt activation. *PloS One* (2012) 7(3):e31939. doi: 10.1371/journal.pone.0031939.
folicular regulatory, and T regulatory cells. *Immunity* (2014) 41(6):1026–39. doi: 10.1016/j.immuni.2014.12.005

50. Kuiper HM, Brouwer M, Linsley PS, van Lier RA. Activated T cells can induce high levels of CTLA-4 expression on B cells. *J Immunol* (1995) 155(4):1767–83.

51. Mabbott NA, Gray D. Identification of co-expressed gene signatures in mouse B1, marginal zone and B2 B-cell populations. *Immunology* (2014) 141(1):79–95. doi: 10.1111/imn.12171

52. Gamez-Diaz L, Neumann J, Jager F, Priessi M, Felber F, Soulas-Sraupel P, et al. Immunological phenotype of the murine Lrbα knockout. *Immunol Cell Biol* (2017) 95(9):789–802. doi: 10.1038/ich.2017.52

53. Stojanovic A, Fiegler N, Brunner-Weinzierl M, Cerwenka A. CTLA-4 is expressed by activated mouse NK cells and inhibits NK cell IFN-gamma production in response to mature dendritic cells. *J Immunol* (2014) 192(9):4184–91. doi: 10.4049/jimmunol.1302091

54. Lougair V, Tabellini G, Baronio M, Patrizi O, Gazzarelli L, Mitsuiki N, et al. CTLA-4 regulates human Natural Killer cell effector functions. *Clin Immunol* (2018) 194:43–5. doi: 10.1016/j.clim.2018.06.010

55. Mirjaccian Martinovic K, Babovic N, Dzodic R, Jurisic V, Matkovic S, Konjevic G. CTLA-4 is involved in the regulation of IL-10 production in hepatocellular carcinoma. *Arthritis Res Ther* (2018) 20(1):62.

56. Halpert MM, Konduri V, Liang D, Chen Y, Wing JB, Paust S, et al. Dendritic cell regulatory dendritic cells suppress T-cell response by cytotoxic T-(1998) 392(6673):245–248.

57. Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. *J Immunol* (1999) 162(8):4511–20.

58. Galea-Lauri J, Darling D, Gan SU, Krivochtchapov L, Kuiper M, Gaken J, et al. CD3−CD56+ natural killer cells to lipopolysaccharide: a role for T cells. *J Immunol* (2019) 13:120. doi: 10.1186/s12967-015-0479-z

59. Santoni G, Amantini C, Morelli MB, Tomassoni D, Santoni M, Marinelli O, et al. Detailed Characterization of Immune Cell Infiltration and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers. *Cancers (Basel)* (2019) 11(10):1533. doi: 10.3390/cancers11101535

60. Salvi S, Fontana V, Boccardo S, Merlo DF, Margallo E, Laurent S, et al. CTLA-4-Mediated inhibition of early events of T cell proliferation. *J Immunol* (2019) 122(1):36–46.

61. Mittal AK, Chaturvedi NK, Rohlfen SA, Gupta P, Joshi AD, Hedge GV, et al. Role of CTLA4 in the proliferation and survival of chronic lymphocytic leukemia. *PloS One* (2013) 8(8):e70352. doi: 10.1371/journal.pone.0070352

62. Santoni G, Amantini C, Morelli MB, Tomassoni D, Santoni M, Marinelli O, et al. CD56+ T cells mediate the cytotoxicity of post-mature dendritic cells to breast cancer cells by upregulating cell cycle inhibitors. *Breast Cancer Res Treat* (2017) 191(1):79–83.

63. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-Mediated inhibition of early events of T cell proliferation. *J Immunol* (1999) 162(10):5813–20. doi: 10.4049/jimmunol.162.10.5813.

64. Mittal AK, Chaturvedi NK, Rohlfen SA, Gupta P, Joshi AD, Hedge GV, et al. Role of CTLA4 in the proliferation and survival of chronic lymphocytic leukemia. *PloS One* (2013) 8(8):e70352. doi: 10.1371/journal.pone.0070352

65. Greenwald RJ, Oosterwegel MA, van der Woude D, Kühl A, Mandelbrot DA, Boussois VS, et al. CTLA-4 regulates cell cycle progression during a primary immune response. *Eur J Immunol* (2002) 32(2):366–73. doi: 10.1002/1521-4141(200202)32:2<366::AID-IMMU2>3.0.CO;2-5

66. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-Mediated inhibition of early events of T cell proliferation. *J Immunol* (1999) 162(10):5813–20. doi: 10.4049/jimmunol.162.10.5813.

67. Santoni G, Amantini C, Morelli MB, Tomassoni D, Santoni M, Marinelli O, et al. Detailed Characterization of Immune Cell Infiltration and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers. *Cancers (Basel)* (2019) 11(10):1533. doi: 10.3390/cancers11101535

68. Salvi S, Fontana V, Boccardo S, Merlo DF, Margallo E, Laurent S, et al. Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. *Cancer Immunol Immunother* (2012) 61(9):1463–72. doi: 10.1007/s00262-012-1211-y

69. Lim YJ, Koh K, Kim K, Chie EK, Kim S, Lee KB, et al. Clinical Implications of Cytotoxic T Lymphocyte Antigen-4 Expression on Tumor Cells and Tumor-Infiltrating Lymphocytes in Extrathoracic Bile Duct Cancer Patients Undergoing Surgery Plus Adjuvant Chemoradiotherapy. *Target Oncol* (2017) 12(2):211–8. doi: 10.1007/s11767-016-0474-7

70. Paulsen EE, Kilvare TK, Rakae M, Richardsen E, Hald SM, Andersen S, et al. CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases. *Cancer Immunol Immunother* (2017) 66(11):1449–61. doi: 10.1007/s00262-017-2039-2
87. Mo X, Zhang H, Preston S, Martin K, Zhou B, Vadalia N, et al. Interferon-
gamma Signaling in Melanocytes and Melanoma Cells Regulates Expression of
CTLA-4. Cancer Res (2018) 78(2):436–50. doi: 10.1158/0008-5472.CAN-
17-1615

88. Pustillo MP, Carosio R, Grillo F, Fontana V, Mastracci L, Morabito A, et al. Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab. Clin Immunol (2020) 215:108428. doi: 10.1016/j.clim.2020.108428

89. Zhang B, Dang J, Ba D, Wang C, Han J, Zheng F. Potential function of
CTLA-4 in the tumourigenic capacity of melanoma stem cells. Oncol Lett
(2018) 16(5):6163–70. doi: 10.3892/ol.2018.9354

90. Liu GV, Liu Y, Lu Y, Qiu YR, Di GH, Lei YH, et al. Short-term memory of
danger signals or environmental stimuli in mesenchymal stem cells: implications for therapeutic potential. Cell Mol Immunol (2016) 13 (3):369–78. doi: 10.1038/cmi.2015.11

91. Liotta F, Angeli R, Cosmi L, Filì L, Manuelli C, Frosali F, et al. Toll-like receptors
3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells (2008) 26(1):279–89. doi: 10.1634/stemcells.2007-0454

92. Bautista-Hernandez LA, Gomez-Olivares JL, Buentello-Volante B, Bautista-
de Lucio VM. Fibroblasts: The Unknown Sentinels Eliciting Immune Responses Against Microorganisms. Eur J Microbiol Immunol (Bpj) (2017) 7(3):151–7. doi: 10.1536/ejmi.2017.00009

93. Zhang Y, Cao HJ, Graf B, Meekins H, Smith TJ, Phippis RP. CD40 engagement up-regulates cyclooxygenase-2 expression and prosta glandin E2 production in human lung fibroblasts. J Immunol (1998) 160(3):1053–7.

94. Zhang M, Tang H, Guo Z, An H, Zhu X, Song W, et al. Splenic stroma drives
mature dendritic cells to differentiate into regulatory dendritic cells. Nat
Immunol (2004) 5(11):1124–33. doi: 10.1038/nii1130

95. Huber LC, Distler O, Turner I, Gay RE, Gay S, Pap T. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatol (Oxford) (2006) 45(6):669–75. doi: 10.1093/rheumatology/kei065

96. Nistico L, Buzzetti R, Pritchard LE, Van der Auwera B, Giovannini C, Bosi E,
et al. The CTLA-4 gene region of chromosome 2q33 is linked to, and
mediates Inhibitory Function of Mesenchymal Stem/Stromal Cells. Int J Mol
Sci (2018) 19(8):2312. doi: 3.1390/ijms19082312

97. Nagaraju K, Raben N, Villalba ML, Danning C, Loeffler LA, Lee E, et al. Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin Immunol (1999) 92(2):161–9. doi: 10.1006/clim.1999.4743

98. Ghannam S, Bouffi C, Djouad F, Jorgensen C, Noel D. Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther (2010) 1(1):2. doi: 10.1186/scrt2

99. Zhou C, Tuong ZK, Frazer IH. Papillomavirus Immune Evasion Strategies
Target the Infected Cell and the Local Immune System. Front Oncol (2019)
9:682. doi: 10.3389/fonc.2019.00682

100. Rouse BT, Horohov DW. Immunosuppression in viral infections. Rev Infect
Dis (1986) 8(6):850–73. doi: 10.1093/clinids/8.6.850

101. Zhou Q, Chen L, Song Y, Ma L, Xiao P, Chen L, et al. Induction of co-
inhibitory molecule CTLA-4 by human papillomavirus E7 protein through
downregulation of histone methyltransferase HDIDM1 expression. Virology
(2019) 538:111–8. doi: virol.2019.10.001

102. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH.
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan
tissue destruction, revealing a critical negative regulatory role of CTLA-4.
Immunity (1995) 3(5):541–7. doi: 10.1016/1074-7613(95)90125-6

103. Mandelbrot DA, Oosterwegel MA, Shimizu K, Yamada A, Freeman GJ,
Mitchell RN, et al. B7-dependent T-cell costimulation in mice lacking CD28 and
CTLA4. J Clin Invest (2001) 107(7):881–7. doi: 10.1172/JCI11710

104. Masteller EL, Chuang E, Mullen AC, Reiner SL, Thompson CB. Structural
analysis of CTLA-4 function in vivo. J Immunol (2000) 164(10):5319–27. doi:
10.4049/jimmunol.164.10.5319

105. Kassardjian A, Shintaku PI, Mostamed NA. Expression of immune
checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and
programmed death-ligand 1 (PD-1), in female breast carcinomas. PloS One
(2018) 13(4):e0195958. doi: 10.1371/journal.pone.0195958

106. Laurent S, Queirolo P, Boero S, Salvi S, Piccioli P, Boccardo S, et al. The
engagement of CTLA-4 on primary melanoma cell lines induces antibody-
dependent cellular cytotoxicity and TNF-alpha production. J Transl Med
(2013) 11:108. doi: 10.1186/1479-5876-11-108

Conflict of Interest: Institutional policy requires VK and WD to declare their
ownership stakes in Diakonos Research, Ltd.

The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.